-
November 6, 2018
R&D Pipeline as of November 2018 -
November 6, 2018
The Second Quarter of FY2018 (April 2018 - September 2018) -
September 28, 2018
Annual Report 2018 -
July 31, 2018
The First Quarter of FY2018 (April 2018 - June 2018) -
May 8, 2018
Annual of FY2017 (April 2017 - March 2018)
-
October 30, 2018
Announcement of in-licensing of technology related to a small molecule tyrosine kinase inhibitor fostamatinib -
September 21, 2018
Kyorin Receives Marketing Approval in Japan for "Beova® Tablets 50mg" for the Treatment of Overactive Bladder -
May 30, 2018
Kissei Announces Negative Topline Results from the additional phase III Clinical Trial evaluating "KPS-0373 (Development Code)" for the Treatment of Spinocerebellar Ataxia -
April 23, 2018
Kissei Announces New President and COO -
January 17, 2018
JR-131, a Long-Acting Erythropoiesis-Stimulating Agent, Demonstrates Equivalence in Phase III Study
